Determination of cytotoxic, apoptotic, necrotic, antimicrobial and antioxidant activities of Aloe vera and Abies cilicia subsp. cilicica

Cancer is one of the most common pathologies in the world, leading to a reduced standard of living and even death for centuries. Despite promising developments in treatment methods in recent years, the expected level of treatment and success hasn’t yet been achieved due to the side effects and cost of treatment methods and the fact that some drugs are still in the trial phase. This situation has encouraged the scientific community to search for natural agents with lower costs and limited side effects. Abies cilicica, also known as fir, and Aloe vera has been used in both food and traditional medicine from the past to the present. In the literature review, it was found that both A. vera and A. cilicica have many beneficial effects, especially anti-inflammatory, antifungal, and wound-healing properties. This study aimed to investigate the antimicrobial, antioxidant, cytotoxic, and apoptotic/necrotic effects of extracts of A. vera from Asphodelaceae and A. cilicica (Ant. Et Kotschy.) subsp. cilicica Carr. from Pinaceae. The best antimicrobial activity was observed against Escerichia coli with a zone diameter of 20.00 ± 3.59 mm and Klebsiella pneumoniae with a zone diameter of 21 ± 5.35 mm. 2KA showed the best effect on antioxidant activity. 2MA + 2KSA showed significant cytotoxic activity on MDA-MB-231 cancer cells. IC50 values of 1EA + 1KA extract (whole A. cilicica and A. vera dissolved in ethanol) against MDA-MB-231 cell line (IC50 458.29 ± 19.01 µg/ml) and MCF-7 cell line (IC50 596.03 ± 5.56 µg/ml) were determined. According to the data obtained from the study, A. vera and A. cilicica were found to have antimicrobial, antioxidant, and cytotoxic effects both alone and synergistically. It is predicted that they can be used especially in cancer treatment

Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects

Abstract Cancer poses a significant global health challenge, with predictions of increasing prevalence in the coming years due to limited prevention, late diagnosis, and inadequate success with current therapies. In addition, the high cost of new anti-cancer drugs creates barriers in meeting the medical needs of cancer patients, especially in developing countries. The lengthy and costly process of developing novel drugs further hinders drug discovery and clinical implementation. Therefore, there has been a growing interest in repurposing approved drugs for other diseases to address the urgent need for effective cancer treatments. The aim of this comprehensive review is to provide an overview of the potential of approved non-oncology drugs as therapeutic options for cancer treatment. These drugs come from various chemotherapeutic classes, including antimalarials, antibiotics, antivirals, anti-inflammatory drugs, and antifungals, and have demonstrated significant antiproliferative, pro-apoptotic, immunomodulatory, and antimetastatic properties. A systematic review of the literature was conducted to identify relevant studies on the repurposing of approved non-oncology drugs for cancer therapy. Various electronic databases, such as PubMed, Scopus, and Google Scholar, were searched using appropriate keywords. Studies focusing on the therapeutic potential, mechanisms of action, efficacy, and clinical prospects of repurposed drugs in cancer treatment were included in the analysis. The review highlights the promising outcomes of repurposing approved non-oncology drugs for cancer therapy. Drugs belonging to different therapeutic classes have demonstrated notable antitumor effects, including inhibiting cell proliferation, promoting apoptosis, modulating the immune response, and suppressing metastasis. These findings suggest the potential of these repurposed drugs as effective therapeutic approaches in cancer treatment. Repurposing approved non-oncology drugs provides a promising strategy for addressing the urgent need for effective and accessible cancer treatments. The diverse classes of repurposed drugs, with their demonstrated antiproliferative, pro-apoptotic, immunomodulatory, and antimetastatic properties, offer new avenues for cancer therapy. Further research and clinical trials are warranted to explore the full potential of these repurposed drugs and optimize their use in treating various cancer types. Repurposing approved drugs can significantly expedite the process of identifying effective treatments and improve patient outcomes in a cost-effective manner